Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advanced Cell Technology, Inc.
Advanced Cell Receives $250,000 Tranche of Funding Commitment
November 7th, 2008
Advanced Cell Technology, Inc. ("ACT") (OTC: ACTC) announced that it has received the initial $250,000 in funding from Transition Holdings Ltd, an Irish institutional investor. The Company previously announced that it would sell $500,000 of one-year 7% convertible debentures over the next 90 days. The proceeds will be used for working capital and general corporate purposes and will support operations while the Company seeks strategic partners for its advanced clinical programs. "We are pleased that an accredited investor with experience investing in emerging companies has chosen to fund ACT in this challenging economic environment," said William M. Caldwell IV, Chairman...
Source: Health Business Week (2008-11-07)
|
